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Abstract The objectives of the current study were to
examine cognitive decline in relation to psychological
wellbeing, HIV disease and treatment characteristics and
baseline variables over a one-year period of time in a group
of HIV-infected patients on long term cART with unde-
tectable viral load in comparison to a HIV-negative control
group. Eighty-two of 95 patients and 43 of 55 controls who
completed a baseline assessment for the Art-NeCo study
underwent a follow-up neuropsychological assessment. A
repeated-measure general linear model analysis was per-
formed to compare the performance at follow-up in com-
parison to baseline between the patients and controls.
Reliable change indices were computed as a measure of
significant change in cognitive function. Compared to
controls, patients overall performed worse on the domain
speed of information processing. In the patient group a
worse performance at follow-up was present for the verbal
fluency domain compared to the controls, in the absence of
a baseline group difference. For the executive function
domain, no group differences were found at follow-up, but
the patients performed worse than the controls at baseline.
We found that cognitive decline was related to more fre-
quent use of recreational drugs and a somewhat heightened
level of irritability and more somatic complaints at base-
line. However, the decliners did not differ from the non-
decliners on any of the HIV-related variables.
Keywords Cognitive decline  Follow-up  Wellbeing 
HIV  RCI
Introduction
HIV-associated neurocognitive disorders (HAND) are still
frequently found in the cART era [1, 2]. Whereas the
prevalence of most severe forms of HAND have vastly
declined, milder forms are still being reported. Over the
years, deficits in various cognitive domains have been
demonstrated, with speed of information processing,
attention, memory and executive function showing the
strongest impairments [2–5].
Several longitudinal studies on neurocognitive decline
and potential predicting factors have been performed
[4, 6, 7]. In their review Cysique et al. [8] found that cART
is associated with stable neuropsychological functioning
over time, especially in clinically stable patients with
undetectable plasma viral loads over a long period of time.
Nevertheless, a longitudinal study with a large study
sample showed cognitive decline at follow-up assessments
in 21 % of patients who were cognitively unimpaired at
baseline [7]. A study in HIV-infected patients with HIV-
related cognitive impairment showed persistent impairment
in 62.8 % of the patients at follow-up (6–124 months)
despite treatment with cART [4].
Some studies used available normative data to determine
significant and clinically relevant cognitive change in indi-
vidual patients. In one study, 192 patients with HIV and 101
HIV negative controls from China were followed for 1 year
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and the results on cognitive assessment of the controls were
used to derive regression-based norms for change [9]. The
scores that were obtained using this approach were adjusted
for practice effects, regression toward the mean, and other
factors that may have an effect on normal test–retest vari-
ability in neurologically stable people (e.g. test–retest
interval, demographics, and overall baseline neuropsycho-
logical competence). Twenty-seven percent of the patient
group showed significant cognitive decline over a one-year
period. This decline was predicted by having AIDS at
baseline, lower nadir CD4 cell count and failure of viral
suppression on cART. Cognitive decline was also related to
decreased independence in activities of daily living. Another
study using a subset of patients from the CHARTER cohort
also investigated cognitive change using a similar approach.
Cognitive change of 436 HIV-infected patients who under-
went 4 to 7 study visits was determined with z-scores based
on published normative data [10]. Results showed cognitive
decline in 22.7 % of the patients, 60.8 % remained
stable and 16.5 % improved. Predictors for cognitive change
were time-dependent treatment status (ART status,
immunosuppression, and plasma and CSF HIV RNA load),
indicators of disease severity (current hematocrit, albumin,
total protein and aspartate aminotransferase), premorbid IQ,
depressive symptoms, and lifetime psychiatric diagnoses.
So far, previous studies that used a statistical approach
to determine cognitive change over time included mixed
cohorts consisting of both patients on cART and cART
naı¨ve patients. In the current study cognitive change was
investigated in a group of HIV-infected patients on long
term cART treatment with undetectable viral load in
comparison to a matched HIV-negative control group. The
aim of this study is twofold. First, we examined cognitive
decline over a one-year period by calculating test–retest
scores for a comprehensive neuropsychological assess-
ment. Second, we identified which HIV disease and treat-
ment characteristics as well as which psychological and
baseline variables are associated with this decline.
Methods
Participants
All participants were recruited as part of the Art-NeCo study
(a prospective Dutch cohort study on NeuroCognition in
HIV-infected patients on long term effective combination
antiretroviral therapy; cART) [5]. Baseline assessment was
performed in 95 HIV-infected patients and 55 HIV-negative
controls. An extensive description of all inclusion and
exclusion criteria have been published previously [5]. Of
these participants, 82 patients and 43 controls underwent a
follow-up neuropsychological assessment yielding a 16, 7 %
(25/150) attrition rate. Reasons for dropping out were lack of
time, lack of interest to participate again and personal rea-
sons like problems at work or at home, unrelated to HIV
status or symptom validity testing. No significant differences
were found between completers and non-completers on the
baseline variables age, education level, sex distribution,
sexual orientation, performance on cognitive domains at
baseline, nadir CD4, time on cART or duration of HIV
infection (p[ .05). At baseline, 34 patients fulfilled the
criteria for asymptomatic neurocognitive impairment and
five for mild neurocognitive disorder. None of the patients
fulfilled the criteria for HIV-associated dementia. The cog-
nitive decrements weremild in nature and cognitive domains
that are typically affected by HIV infection like executive
functioning and memory were unimpaired in our patient
sample [5].
Procedures
At both study visits participants completed a comprehensive
neuropsychological assessment measuring eight cognitive
domains (speed of information processing, learning, memory,
executive function, attention/working memory, motor
function, visuoconstruction and verbal fluency). Also, a self-
report questionnairewas completed, the symptom checklist—
revised (SCL-90-R), to measure psychological distress and
somatic complaints. At baseline, a questionnaire on alcohol
and other recreational drug use was completed by all partici-
pants and a rapidHIV test was performed in all controls. Also,
participants without contraindications underwent an MR
examination at baseline and symptom validity testing was
performed. Baseline details of theArt-NeCo in- and exclusion
criteria, the neuropsychological test battery and the MRI
analyses have been reported in a previous publication [5].
Medical ethical approval for this study and written informed
consent from all study participants were obtained (CMO
Region Arnhem–Nijmegen #2011/267).
Statistical Analyses
Raw test scores of the individual tests of the baseline and
follow-up neuropsychological test battery were trans-
formed into standardized z-scores. Test scores were trans-
formed on the basis of the baseline test score distribution of
the patient- and control group taken together, with higher
scores indicating a better performance for all tests. Cogni-
tive domain scores were computed by averaging the con-
tributing tests to each of the cognitive domains [11].
A repeated measures General Linear Model (GLM) was
executed to compare the performance at follow-up in
comparison to baseline between the patients and controls.
Age, sex and estimated premorbid IQ were entered as
covariates. Alpha was set at 0.05 for all analyses.
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Determination of Cognitive Decline
Next, analyses were performed to establish which patients
deteriorated at follow-up compared to baseline, using the
change in performance in the controls as benchmark.
Reliable change indices (RCIs) were computed per patient
as a measure of individual significant change on the cog-
nitive tests after a one-year retest interval. According to the
procedure outlined in Chelune et al. [12], difference scores
of the individual test scores between the first (T1) and
second (T2] assessment were calculated for each individual
patient (ptx) and a mean difference score was calculated for
the control group as a whole (ct). The difference score for
each patient was subtracted by the mean difference score of
the control group as whole, using the following formula:
(T2ptx-T1ptx) – (T2ct-T1ct). Next, the standard error of
difference (Sdiff) was calculated for each of the test scores
per patient, following the procedures outlined in Maassen
[13], using the following formula: Sdiff =
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
SDT12ct
 þ SDT22ct
 ð1rT1T2Þ
q
Finally, the difference score of each patient per test was
divided by the standard error of difference in order to
calculate the RCI index per test per patient. Next, indi-
vidual RCIs per test were averaged into the eight cognitive
domains. Patients with a mean RCI domain
score C -1.645 [12] were considered as ‘cognitive
decliners’ on that domain. Subsequently, individual
patients were classified as either overall cognitive decliner,
defined as showing a reliable decline on at least one cog-
nitive domain, or non-decliner. Subsequently, overall
cognitive decliners were compared to non-decliners on the
SCL-90-R subscale performance, alcohol and drug use,
HIV disease and treatment variables, age and MRI mea-
sures at baseline.
Results
Only participants who passed symptom validity testing
were included in all analyses [5]. Mean follow-up interval
was 12.2 months (range 10.1–18.6 months). Table 1 shows
the baseline demographic characteristics, SCL-90-R scores
and MRI measures of the patients and controls who par-
ticipated in the follow-up assessment and the HIV disease
and treatment characteristics for the patients.
Baseline Versus Follow-up Cognitive Performance
Figure 1 shows the baseline and follow-up cognitive per-
formance for the patients and controls for the individual
cognitive domains. Repeated-measure GLM analyses
showed an overall better performance at follow-up than at
baseline for both groups for the domains speed of infor-
mation processing, executive function and visuoconstruc-
tion (F-values[ 4.6, p\ .05). An overall group difference
was found on the domain speed of information processing
(F = 5.1, p = .025, gp
2 = .041), with the patients per-
forming worse than the controls. A significant group 9
time interaction was found for the domains executive
function (F = 10.1, p = .002, gp
2 = .077) and verbal flu-
ency (F = 4.2, p = .04, gp
2 = .034). Post-hoc t-tests
demonstrated that at follow-up, but not at baseline, the
performance of the patients on the verbal fluency domain
was worse than the controls (t (123) = -2.129, p\ .05
and t (123) = -0.666, n.s., respectively). Between-group
differences were found at baseline, but not at follow-up, for
the domain executive function (t (123) = -2.249, p\ .05
and t (123) = -0.493, n.s., respectively).
Cognitive Decliners Versus Non-decliners
Of the total group of 82 patients, 7 patients showed cognitive
decline on the domain verbal fluency (8.5 %), 2 on the domain
visuoconstruction (2.4), 1 on the domain speed of information
processing (1.2 %) and 1 on motor function (1.2 %). No
decliners were found in any of the other domains. In total, 11
patients were classified as being overall cognitive decliners
(13.4 %). These cognitive decliners were subsequently com-
pared to the non-decliners on SCL-90-R subscale perfor-
mance, alcohol and drug use, HIV disease and treatment
variables, age and MRI measures at baseline. The cognitive
decliners reported more complaints on the subscales somatic
complaints (F(1,81) = 5.4, p\ .05) and anger-hostility
(F(1,81) = 5.9, p\ 0.02) of the SCL-90-R at baseline com-
pared to the non-decliners. With respect to any of the other
baseline characteristics, the proportion of frequent users of
recreational drugs was higher in the cognitive decliners than
the non-decliner group (v2(1) = 6.56, p\ .01). No differ-
ences were found between both groups on any of the other
baseline or HIV-related baseline characteristics.
Discussion
The present study investigated cognitive change over a
one-year period in a virologically stable HIV-infected
patient group in comparison to a healthy matched control
group. Also, we examined whether HIV disease and
treatment characteristics and psychological baseline vari-
ables were associated with cognitive decline.
Compared to the controls, the patients overall performed
worse on the domain speed of information processing, but
no group 9 time interaction was found for this domain.
For the domain verbal fluency, a group 9 time interaction
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effect was found, showing a worse performance at follow-
up in the patient group compared to the controls, in the
absence of a baseline group difference. For the domain
executive function, no group difference was found at fol-
low-up, but the patients performed worse than the controls
at baseline. Our findings clearly show that a lower per-
formance in speed of information processing, both at
baseline and follow-up, is a robust finding, in line with
previous studies [2, 14] that also report impairments in this
domain in HIV-infected individuals on cART. With respect
to the follow-up performance difference in the domain
verbal fluency for the patients, it is interesting to note that
while both groups improve on an absolute level, the
improvement in the patients was smaller than in the con-
trols. Also, it should be noted that this domain only consists
of one test, which also relies on processing speed. In the
present subsample of the Art-NeCo sample, a baseline
difference between patients and controls was found for
executive function, a finding that disappeared at follow-up.
Interestingly, this baseline difference was not found in the
total Art-NeCo group [5], indicating that this effect may
not be very reliable.
At an individual level, most cognitive decliners (based
on RCI analyses using the control group performance as
reference) were found in the domain verbal fluency.
Comparing the patients who reliably declined on at least
Table 1 Demographic
variables, SCL-90-R, MRI
correlates and treatment
characteristics at baseline
Characteristic Patients (n = 82) Controls (n = 43)
Age (years) [mean (SD)] 48.7 (9.9) 51.4 (11.1)
Sex
Men 72 (87.8 %) 34 (79.1 %)
Women 10 (12.2 %) 9 (20.9 %)
Education level [median (range)]3 6 (2–7)* 6 (4–7)
Estimated IQ [mean (SD)] 98.7* (14) 106.8 (11.4)
Nadir CD4 cell count (cells/lL) [mean (IQR)] 222 (100–310) –
Duration HIV-infection (years) [mean (SD)] 9.6 (6.4) –
Duration cART treatment (years) [mean (SD)] 8.1 (5.8) –
Regular alcohol use1 25 (30.5 %) 18 (41.9 %)
Regular drug use2 7 (8.5 %) 3 (7 %)
SCL-90-R [mean (SD)]
Total 131 (38.3) 114 (26.2)
Agoraphobia 8 (2.3) 8 (1.2)
Anxiety 14 (4.4) 12 (3.3)
Depression 25 (8.9) 21 (6.6)
Somatic complaints 18 (5.5) 15 (4.3)
Cognitive performance difficulty 14 (5.1) 12 (3.4)
Interpersonal sensitivity 25 (9.1) 23 (6.4)
Anger-hostility 8 (2.3) 7 (1.5)
Sleep disturbances 6 (2.6) 4 (1.6)
MRI volumetry [mean (SD)]
Grey matter volume4 619.3 (46.1) 613.8 (39.6)
White matter volume4 602.8 (39.8) 610.5 (25.7)
1 Regular alcohol use is use of alcohol for three or more times a week or binge drinking on two subsequent
days
2 Regular drug use is use of a drug for four times or more times a month
3 Education level was recorded using seven categories based on the Dutch educational system which uses
education levels instead of years of formal education (approximate Anglo–Saxon equivalent in years of
education is presented between brackets): Level 1 = less than 6 years of primary education (1–5); Level
2 = completed primary education (6), Level 3 = more than 6 years of primary education, without a
secondary school diploma (7–8), Level 4 = lower vocational training (7–9); Level 5 = advanced voca-
tional training or lower professional education (7–10); Level 6 = advanced professional training or upper
secondary school (7–17); Level 7 = academic degree ([18 years)
4 Relative Grey- and White matter: grey matter volume/total intracranial volume (TIV) 9 all patient TIV
mean, white matter volume/total intracranial volume (TIV) 9 all patient TIV mean
* p\ 0.05
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one of the cognitive domains with those who remained
cognitively stable, we found that the decliners reported
more psychological complaints, specifically related to
irritability towards others and somatic complaints at base-
line. However, the decliners did not differ from the non-
decliners on any of the HIV-related variables, such as nadir
CD-4 cell count, duration of infection and years of cART
use. This suggests that the higher level of somatic com-
plaints cannot be explained by illness-related somatic
factors. The decliners, however, were more often frequent
users of recreational drugs than the non-decliners, which
may potentially underlie the somewhat lower somatic
wellbeing in this subsample [15]. However, it should be
stressed that the total group of recreational drug users and
the number of overall cognitive decliners were small,
therefore this result should be interpreted with caution. No
differences between decliners and non-decliners were
found on depressive symptoms and anxiety, two psycho-
logical domains that are frequently related to worse cog-
nitive performance [16–18].
A limitation of the current study is the relatively short
interval of one year between the baseline and follow-up
assessment. Particularly in a well-treated HIV-infected
patient sample without co-morbidities, longer follow-up
periods of five or even ten years may contribute to our
knowledge of long-term consequences of HIV infection on
cognitive functions in patients who are stable on cART. On
the other hand, Becker et al. [19] demonstrated cognitive
decline already after a six-month follow-up assessment, a
finding that was found to be related to medication adher-
ence. This further emphasizes the need and clinical rele-
vance to examine cognitive decline over time in HIV-
infected patients.
In conclusion, the findings of the current study show that
cognitive decline at group level is small. We only found a
decline in speed of information processing after one year.
At an individual level, cognitive decline was present in
only a small number of patients and was related to some-
what more psychological distress and more frequent use of
recreational drugs. No relation between cognitive decline
over time and HIV disease and treatment characteristics
was found.
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